cns.jpg (2811 bytes)



Journal Home
Editorial Board
Instructions for Contributors
Subscription Rates

Neva Press, Inc. 2005

CNS Drug Reviews

Table of Contents

Volume 5, Supplement 1

Session I.  New Approaches to the Control of Pain
1 Goals of the Symposium
A. Scriabine, Chair of The Symposium
2 Neuronal Nicotinic Receptors:  New Opportunity for CNS Drugs
M. Williams, Abbott Laboratories, Abbott Park, IL
3 Use of Knockout Mice for Screening of Nicotinic Compounds for Treatment of CNS Disorders
M. Picciotto, Yale University, New Haven, CT
4 Sodium Channel Subtypes as Targets for Novel Analgesics
John C. Hunter, Roche Bioscience, Palo Alto, CA
6 The Search for Novel Antimigraine Therapy
A. Parsons, SmithKline Beecham, King of Prussia, PA
7 5HT1F Receptors and Migraine:  From Cloning to the Clinic
David L. G. Nelson, Lilly Research Laboratories, Indianapolis, IN
Session II.   New Drugs for Treatment of Neurodegenerative Diseases
8 Neuroimmunophilin Ligands as Treatment for Neurodegenerative Disorders
Joseph P. Steiner, Guilford Pharmaceuticals, Inc., Baltimore, MD
9 The Evolving Pharmacology of AMPA Subtype Glutamate Receptors
F. S. Menniti, Pfizer Laboratories, Groton, CT
10 Subunit Selective NMDA Receptor Antagonists for the Treatment of Neurological Diseases
S. Donevan, Warner-Lambert-Parke-Davis, Ann Arbor, MI
11 AR-R 15896AR - A Low Affinity Use Dependent NMDA Antagonist for Stroke - A Preclinical Review
G. Palmer, Astra Zeneca, Rochester, NY
12 Approaches Toward Development of a Disease Modifying Treatment for Alzheimer's Disease
T. Verdoorn, Bristol-Myers-Squibb, Wallingford, CT
13 Neuroactive Steroids (Epalons) in the Treatment of Psychiatric and Neurological Disorders
J. E. Barrett, Wyeth-Ayerst Laboratories, Princeton, NJ
Session III.   Targets for Drug Discovery and Methods for Evaluation of CNS Drugs
14 Regulation of K+ Channels and Their Genes
L. Kaczmarek, Yale University, New Haven, CT
15 Metabotropic Glutamate Agonists:  Novel Treatment for Psychiatric Disorders
G. Marek, Yale University, New Haven, CT
16 BK(Ca) Channels in Planar Bilayers and Whole Cells:  A Potential Target for Drug Screening
E. Moczydlowski, Yale University, New Haven, CT
17 Inducible Transgenic Tools for CNS Drug Discovery
E. Nestler, Yale University, New Haven, CT
18 Serotonin Transporter as a Target for Drug Development
G. Rudnick, Yale University, New Haven, CT
19 The Use of Radiotracer Imaging in Therapeutic Drug Development
R. Innis, Yale University, New Haven, CT
20 Quantitative Assessment of Neuronal Damage in a Transgenic Murine Model of Alzheimer's Disease
Ronald F. Mervis, Jody McKeon, Timothy Pindell, Deborah Campbell, Ivan Lieberburg, Dale Schenk, Karen Kahn and Dora Games